The SGLT-2 inhibitor Jardiance expanded the indication to HFpEF. Beringer Ingelheim Korea and Lilly Korea announced on the 26th that Jardiance has been approved by the MFDS to expand its indication as a treatment for chronic heart failure regardless of left ventricular contraction function (hereinafter referred to as heart rate). Jardiance was approved by HFrEF last November. It is expanded by preserving the cardiac output rate, and it can be used to treat patients with chronic heart failure regardless of the cardiac output rate. Heart failure is divided into reduction, vigilance, and preservation according to heart rate. The ejection rate is reduced by less than 40%, the boundary is 40 to 50%, and more than 50% is co